Aernoud Fiolet

226 Chapter 8 infarction. 21, 22 However, the number of patients enrolled between days 4 and 7 in the COLCOT trial was modest, and the effects on individual components of the primary outcome were inconsistent. In contrast to COLCOT, the LoDoCo2 trial did not include patients early after an acute myocardial infarction, but included patients that were clinically stable for at least six months. Our results from LoDoCo2 trial provide support for the conclusion that the benefits of colchicine are consistent if started months or years after ACS. LIMITATIONS Our analyses have some limitations.The results presented in the currentmanuscript originate from a subgroup analysis of the LoDoCo2 trial.While a subgroup analysis of a randomized clinical trial generally preserves the integrity of randomization some potential of residual confounding remains. The LoDoCo2 trial required patients to be clinically stable for at least six months, precluding direct comparison to patients with very recent ACS. A small proportion of patient population did not have a history of prior ACS, limiting power to detect a difference between patients with no prior ACS and prior ACS. CONCLUSIONS The benefits of colchicine are consistent irrespective of history and timing of prior ACS, thereby highlighting the importance of compliancewith long-term secondary prevention therapies, including the use of anti-inflammatory therapy.